169 related articles for article (PubMed ID: 38095707)
41. Unilateral versus bilateral injections of botulinum toxin in patients with adductor spasmodic dysphonia.
Bielamowicz S; Stager SV; Badillo A; Godlewski A
J Voice; 2002 Mar; 16(1):117-23. PubMed ID: 12002878
[TBL] [Abstract][Full Text] [Related]
42. [Treatment of spasmodic dysphonia with botulinum toxin].
Klap P; Marion MH; Perrin A; Fresnel-Elbaz E
Ann Otolaryngol Chir Cervicofac; 1991; 108(8):477-82; discussion 482-3. PubMed ID: 1789624
[TBL] [Abstract][Full Text] [Related]
43. Validation of the OMNI vocal effort scale in the treatment of adductor spasmodic dysphonia.
Shoffel-Havakuk H; Marks KL; Morton M; Johns MM; Hapner ER
Laryngoscope; 2019 Feb; 129(2):448-453. PubMed ID: 30315575
[TBL] [Abstract][Full Text] [Related]
44. Vocal Parameters and Self-Perception in Individuals With Adductor Spasmodic Dysphonia.
Rojas GVE; Ricz H; Tumas V; Rodrigues GR; Toscano P; Aguiar-Ricz L
J Voice; 2017 May; 31(3):391.e7-391.e18. PubMed ID: 27866691
[TBL] [Abstract][Full Text] [Related]
45. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.
Blitzer A; Brin MF; Stewart CF
Laryngoscope; 1998 Oct; 108(10):1435-41. PubMed ID: 9778279
[TBL] [Abstract][Full Text] [Related]
46. Botox treatment in adductor spasmodic dysphonia: a meta-analysis.
Boutsen F; Cannito MP; Taylor M; Bender B
J Speech Lang Hear Res; 2002 Jun; 45(3):469-81. PubMed ID: 12069000
[TBL] [Abstract][Full Text] [Related]
47. Common practices in botulinum toxin injection for spasmodic dysphonia treatment: A national survey.
Shoffel-Havakuk H; Rosow DE; Lava CX; Hapner ER; Johns MM
Laryngoscope; 2019 Jul; 129(7):1650-1656. PubMed ID: 30582627
[TBL] [Abstract][Full Text] [Related]
48. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.
Troung DD; Rontal M; Rolnick M; Aronson AE; Mistura K
Laryngoscope; 1991 Jun; 101(6 Pt 1):630-4. PubMed ID: 2041443
[TBL] [Abstract][Full Text] [Related]
49. Botulinum toxin injection into the intrinsic laryngeal muscles to treat spasmodic dysphonia: A multicenter, placebo-controlled, randomized, double-blinded, parallel-group comparison/open-label clinical trial.
Hyodo M; Nagao A; Asano K; Sakaguchi M; Mizoguchi K; Omori K; Tada Y; Hatakeyama H; Oridate N; Naito K; Iwata Y; Shinomiya H; Hara H; Sanuki T; Yumoto E
Eur J Neurol; 2021 May; 28(5):1548-1556. PubMed ID: 33393175
[TBL] [Abstract][Full Text] [Related]
50. Botulinum toxin injections for the treatment of spasmodic dysphonia.
Watts CC; Whurr R; Nye C
Cochrane Database Syst Rev; 2004; 2004(3):CD004327. PubMed ID: 15266530
[TBL] [Abstract][Full Text] [Related]
51. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
[TBL] [Abstract][Full Text] [Related]
52. Practice Patterns and Barriers in Botulinum Toxin Injection for the Treatment of Voice Disorders.
McGarey PO; Simpson CB; Daniero JJ
J Voice; 2022 Jan; 36(1):113-118. PubMed ID: 32467003
[TBL] [Abstract][Full Text] [Related]
53. Analysis of factors affecting botulinum toxin results in spasmodic dysphonia.
Inagi K; Ford CN; Bless DM; Heisey D
J Voice; 1996 Sep; 10(3):306-13. PubMed ID: 8865102
[TBL] [Abstract][Full Text] [Related]
54. Safety of simultaneous bilateral botulinum toxin injections for abductor spasmodic dysphonia.
Stong BC; DelGaudio JM; Hapner ER; Johns MM
Arch Otolaryngol Head Neck Surg; 2005 Sep; 131(9):793-5. PubMed ID: 16172357
[TBL] [Abstract][Full Text] [Related]
55. Sulcus vocalis in spasmodic dysphonia-A retrospective study.
Nerurkar NK; Agrawal D; Joshi D
Am J Otolaryngol; 2021; 42(3):102940. PubMed ID: 33545449
[TBL] [Abstract][Full Text] [Related]
56. Prospective study of patients' subjective responses to botulinum toxin injection for spasmodic dysphonia.
Liu TC; Irish JC; Adams SG; Durkin LC; Hunt EJ
J Otolaryngol; 1996 Apr; 25(2):66-74. PubMed ID: 8683655
[TBL] [Abstract][Full Text] [Related]
57. Impact of an Upper Respiratory Tract Infection on Botulinum Toxin Efficacy in Spasmodic Dysphonia Patients.
Kirke DN; Kaye R; Blitzer A
Laryngoscope; 2020 Jul; 130(7):1746-1749. PubMed ID: 31508822
[TBL] [Abstract][Full Text] [Related]
58. OnabotulinumtoxinA for adductor spasmodic dysphonia (ADSD): Functional results and the role of dosage.
Marchese MR; D'Alatri L; Bentivoglio AR; Paludetti G
Toxicon; 2018 Dec; 155():38-42. PubMed ID: 30315835
[TBL] [Abstract][Full Text] [Related]
59. Effects of botulinum toxin on pathophysiology in spasmodic dysphonia.
Bielamowicz S; Ludlow CL
Ann Otol Rhinol Laryngol; 2000 Feb; 109(2):194-203. PubMed ID: 10685573
[TBL] [Abstract][Full Text] [Related]
60. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
